Graphjet Technology Announces Agreement with UK’s Quantum Science for Nanomaterials and Quantum Dot Technologies

Graphene and graphite producer Graphjet Technology Sdn. Bhd. (Graphjet) has announced a new partnership with UK headquartered Quantum Science Ltd. that will enhance both companies’ innovation pipelines.

Image Credit: Graphjet Technology Sdn. Bhd.

Graphjet’s memorandum of agreement with Quantum Science, the world-leader in the development of quantum dot (QD) solutions, will see the companies explore the technical and commercial opportunities of working together. 

Plans are already underway for the two parties to create a flagship new materials platform, with work due to start as soon as the agreement is finalised in early 2023. 

The companies will co-develop a range of new products that accelerate technological advances, with the aim of bringing new growth opportunities and improving the lives of hundreds of millions of people around the world. 

Patrick Teh, Director UK and Europe at Graphjet, said that the collaboration with Quantum Science will “combine the strength and wisdom from both companies”, adding that “the perfect property synergy of graphene and QDs can make a revolution”. 

Quantum Science’s QD technology promises to revolutionise the multi-billion dollar industries reliant on shortwave infrared (SWIR) imaging and sensing by vastly simplifying how QDs can be manufactured and applied. 

The company’s state-of-the-art solutions have promising applications for fields including facial recognition, advanced IoT sensors, night vision enhanced security monitoring, and long-range automotive Lidar, among many others. 

The memorandum of agreement will see Quantum Science share its expertise with Graphjet to advance both companies’ technology offerings to their customers. 

Kuala Lumpur-based Graphjet transforms waste palm kernel shells into high-demand graphene materials for a range of technical industries. 

In August, it was announced that Graphjet will become a wholly-owned subsidiary of Energem, a special purpose acquisition company, after which it will be renamed Graphjet Technology and will be listed on the Nasdaq Global Market – a stock market that lists companies with an overall global leadership and international reach with their products or services - under the ticker symbol ‘GTI’. 

The partnership between Graphjet and Energem has been approved by the boards of directors of Energem and Graphjet, subject to, among other things, the approval by Energem’s shareholder, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions, including a registration statement being declared effective by the SEC and approval by The Nasdaq Stock Market to list the securities of the combined entity. 

Aiden Lee, CEO of Graphjet, said: “We are excited to team up with Quantum Science, a world leading QD innovator and developer, to advance our graphene products development and offerings. It will enable our ever-increasing customer base to access to the most advanced materials platform at unparalleled cost advantages, introducing new features and bringing significant value to their businesses. We are pleased to continue our rapid forward progress as a sustainably sourced provider of graphite and graphene at a price that can be 80% less than competitors in a market using carbon-intensive production means resulting in lesser quality materials.” 

Dr Hao Pang, CEO of Quantum Science, commented: “We are delighted to partner with GTI, a world-leading graphite and graphene producer, to advance our innovation and product offerings to our customers. Both QD and graphene materials have great potential synergies and offer unparalleled technical advantages for a wide range of applications, that can only benefit our customers, end-users and stakeholders alike.” 

For more information about Quantum Science Ltd, please visit: www.quantumscis.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.